Colorectal Cancer Diagnostics Market Growth Report | 2023-2028

[Research Report] The colorectal cancer diagnostics market size is expected to grow from US$ 10,374.68 million in 2022 to US$ 16,996.48 million by 2028; it is estimated to record a CAGR of 8.7% from 2023 to 2028.

The colorectal cancer diagnostics market is segmented based on modality, end user, and geography. The report offers insights and in-depth market analysis, emphasizing parameters such as drivers, trends, opportunities, and competitive landscape analysis of leading market players across various regions. It also includes analyses of the impact of the COVID-19 pandemic across major regions.

Market Insights

Launches of New Products Drives Colorectal

Major players in the colorectal cancer diagnostics market manufacture a wide range of devices that help reduce the burden of colorectal cancer and other associated indications such as colon polyps, Crohn’s disease, colitis, and irritable bowel syndrome. In July 2022, US Digestive Health (USDH), a network of top-rated gastrointestinal (GI) practices, announced the commercialization of AI-assisted colonoscopy screenings with the country’s largest installation of Genious Intelligent GI endoscopy modules. These modules are expected to help physicians identify hard-to-detect and potentially cancerous polyps in real time. With the launch of this device, patients throughout southeastern, southwestern, and central Pennsylvania can now access AI-assisted colonoscopy with enhanced capabilities. In September 2020, Olympus Corporation announced the launch of ENDO-AID, a cutting-edge platform powered by artificial intelligence (AI). The platform includes ENDO-AID CADe application (app), a computer-aided endoscopic method for the detection of different conditions of the colon. This new AI platform enables the real-time display of automatically detected suspicious lesions and works in combination with its EVIS X1. Thus, the frequent developments and new product launches drive the colorectal cancer diagnostics market growth.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Get 10% FREE CUSTOMIZATION

Colorectal Cancer Diagnostics Market: Strategic Insights

Colorectal Cancer Diagnostics Market

• 
  CAGR (2022 - 2028)

  8.7%
• Market Size 2022
  US$ 10.37 Billion
• Market Size 2028
  US$ 17 Billion

Market Dynamics

GROWTH DRIVERS

• Increasing Prevalence of Colorectal Cancer
• Launches of New Products

FUTURE TRENDS

• Artificial Intelligence in Colonoscopy

OPPORTUNITIES

• Growing Awareness of Colorectal Cancer

Key Players

• Medtronic Plc
• Illumina Inc
• Clinical Genomics Technologies Pty Ltd
• EDP Biotech Corp
• Epigenomics AG
• F Hoffmann La Roche Ltd
• Quest Diagnostics Inc
• Novigenix SA
• Siemens Healthineers AG

Regional Overview

• North America
• Europe
• Asia-Pacific
• South and Central America
• Middle East and Africa

Market Segmentation

Modality

• Imaging Tests
• Stool Based Tests

End User

• Hospitals
• Diagnostic Laboratories
• Cancer Research Institutes

Download Free Sample

   Buy Now   

• Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Modality-Based Insights

Based on modality, the colorectal cancer diagnostics market is bifurcated into stool-based tests and imaging tests. In 2022, the imaging tests segment held a larger share of the colorectal cancer diagnostics market and is anticipated to register a higher CAGR during the forecast period. The use of imaging tests in colorectal cancer diagnostics has evolved over the last few years. Imaging results are instrumental in surveillance, diagnosis, staging, treatment selection, and follow-up scheduling. Imaging tests involve looking at the structure of the colon and rectum for the presence of any abnormal areas. Imaging examinations use scopes, tube-like instruments with a light and tiny video camera at their end, inserted into the rectum. These tests scan the inside of the colon and rectum for any abnormal areas that might be cancer or polyps. These tests are used less often than stool-based tests and require more preparation beforehand and have some associated risks, unlike stool-based tests. The imaging tests is further classified into colonoscopy, CT colonography, flexible sigmoidoscopy, capsule endoscopy, and others.

Colonoscopy segment held the largest share of the market in 2022. However, CT colonography is expected to grow at a faster pace during the forecast period. CT colonography aids in the morphological analysis of wall deformities, providing information required for the preoperative assessment of T staging in colorectal cancer. As per the guidelines of Response Evaluation Criteria in Solid Tumors (RECIST), CT is the most widely used modality for assessing treatment response in patients with metastasized colon and rectal tumors. The common advantages of CT colonography are as follows: it is quick and safe, it helps to visualize the entire colon, and no sedation is required to perform the test. This test is recommended to be performed every five years in asymptomatic patients with average risk.

End User-Based Insights

Based on end user, the colorectal cancer diagnostics market is segmented into hospitals, diagnostic laboratories, cancer research institutes, and others. The hospitals segment accounted for the largest market share in 2022 and is anticipated to register the highest CAGR during the forecast period.

The colorectal cancer diagnostics market players adopt organic strategies such as product launch and expansion to expand their geographic footprint and product portfolios and meet the growing demands. Inorganic growth strategies adopted by market players allow them to expand their businesses and enhance their geographic presence. Additionally, these growth strategies help companies strengthen their clientele and enlarge their product portfolios.

• In December 2022, Epigenomics licenses protein biomarker technology for blood-based colorectal cancer test. The company has licensed from The University of Texas MD Anderson Cancer Center certain patent and technology rights to biomarkers associated with colorectal cancer detection.
• In August 2021, Illumina Acquired GRAIL to Accelerate Patient Access to Life-Saving Multi-Cancer Early-Detection Test. GRAIL's Galleri blood test detects 50 different cancers before they are symptomatic. Illumina's acquisition of GRAIL will accelerate access and adoption of this life-saving test worldwide.

Colorectal Cancer Diagnostics Market Report Scope

Download Free Sample

   Buy Now   

• Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Company Profiles

• Medtronic Plc
• Illumina Inc
• Clinical Genomics Technologies Pty Ltd
• EDP Biotech Corp
• Epigenomics AG
• F. Hoffmann-La Roche Ltd
• Quest Diagnostics Inc
• Novigenix SA
• Siemens Healthineers AG
• Bruker Corp
• Eiken Chemical Co., Ltd.